The US FDA has approved sevabertinib for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors harbor HER2 tyrosine kinase domain-activating mutations and who have received at least one prior systemic therapy. Clinical evidence In a clinical trial of 122 patients, sevabertinib achieved an objective response rate of 71%, including a 2.9% complete response rate and a 69% partial response rate.
The median duration of response was 9.2 months. Dosage and administration Available in tablet form Recommended dosage: 20 mg orally twice daily with food, continued until disease progression or unacceptable toxicity Contraindications – None Warning and precautions Diarrhea Hepatoxicity Interstitial lung disease/pneumonitis Ocular toxicity Pancreatic enzyme elevation Embryo-fetal toxicity Adverse reactions Most common adverse…
